Frequently Asked Questions

Why are specific preclinical models required for neurobehavioral assessments of AAV therapies?

Certain biological models possess a complex neuroanatomy and an immune system that more closely mirrors human biology compared to other species. This allows for a more predictive evaluation of cognitive, motor, and sensory functions that may be affected by a CNS-directed genetic therapy.

What is the primary objective of these assessments within an IND-enabling study?

The objective is to build a comprehensive safety profile by detecting potential off-target or adverse neurological effects with high sensitivity. This process is designed to identify subtle changes in function or behavior that might not be apparent in standard toxicology evaluations, directly minimizing clinical risk.

How does the route of administration (ROA) influence the study design?

The ROA is a critical determinant of study design, influencing both vector biodistribution and potential interactions with the host immune system. Considering that diverse AAVs are naturally present in human tissues (PMID: 15163731), the delivery route can significantly impact how a therapeutic vector is affected by pre-existing immunity. A study design must therefore be tailored to the specific ROA to ensure the neurobehavioral assessments accurately evaluate tissues with potential vector exposure while accounting for these immunological variables.

Additional Insights

Assessing the safety of advanced therapeutics and complex biologics for the central nervous system requires a highly specialized approach. Applying proven intelligence in preclinical toxicology accelerates these programs, building on our core scientific team’s 100% successful IND submission rate since 2019, a track record established prior to the launch of Franklin Biolabs in 2024.

For AAV-based vectors targeting neurological indications, standard preclinical testing batteries are insufficient. The intricate nature of the CNS demands sensitive, specific neurobehavioral assessments capable of detecting subtle functional changes. These evaluations form a key component of any IND-enabling toxicology study conducted under GLP conditions.

The method of vector administration is a significant variable. The translational feasibility of certain delivery routes can impact vector distribution and subsequent transgene expression. A robust preclinical strategy must account for these variables, designing functional assessments that align with the intended clinical administration and anticipated biodistribution profile.

A tailored, science-based preclinical strategy does not rely on a fixed template. The design of a neurobehavioral battery is customized based on the AAV capsid (e.g., AAV9, AAV-Rh10, or engineered variants), the target indication, and the known biology of the transgene.

Core components of a comprehensive neurobehavioral assessment battery include:

• Motor Function: Analysis of gait, balance, and fine motor coordination.
• Cognitive Evaluation: Tasks designed to assess learning, memory, and executive function.
• Sensory Response: Quantitative assessment of response to auditory, visual, or tactile stimuli.
• Clinical Observations: Structured scoring of home-cage activity, social interaction, and general well-being by trained veterinary staff.

By integrating these specialized assessments into GLP-compliant toxicology programs, we provide the high-resolution safety data required to de-risk novel CNS-targeted therapies and support regulatory submissions.

Return to Preclinical | Translational Services